Daptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens

Abstract

The aim of this review is to summarize the historical background of drug resistance of Gram-positive pathogens as well as to describe in detail the novel lipopeptide antibiotic daptomycin. Pharmacological and pharmacokinetic aspects are reviewed and the current clinical use of daptomycin is presented. Daptomycin seems to be a reliable drug in the treatment of complicated skin and skin structure infections, infective right-sided endocarditis, and bacteremia caused by Gram-positive agents. Its unique mechanism of action and its low resistance profile, together with its rapid bactericidal action make it a favorable alternative to vancomycin in multi-drug resistant cocci. The role of daptomycin in the treatment of prosthetic material infections, osteomyelitis, and urogenital infections needs to be evaluated in randomized clinical trials.

Keywords:

• daptomycin
• multi-drug resistance
• methicillin-resistant Staphylococcus aureus (MRSA)
• pneumonia
• urinary tract infection
• left-sided endocarditis

Disclosure

Andres Beiras-Fernandez has received research grants from Novartis for infection projects/studies, and is a member of a Novartis Speakers’ Panel.